Assistant Professor
Dr. P.P (Paul) Geurink, PhD
Area(s) of expertise:
Chemical biology, Drug discovery, High-throughput screening
Chemical biology, Drug discovery, High-throughput screening
&w=400&h=400)
Introduction
I am group leader at the division of Chemical Biology & Drug Discovery within the Cell and Chemical Biology (CCB) Department and head of the LUMC High-Throughput Screening Center.
After obtaining my masters in chemistry I did a PhD at the Leiden Institute of Chemistry in the field of chemical biology. I next moved to the Netherlands Cancer Institute to conduct postdoctoral research and spent a short time at the MRC-LMB in Cambridge, UK. Mid-2016 I started at the LUMC in the group of the late professor Huib Ovaa and since 2020 as group leader. The screening facility I am heading has been selected as the center of expertise within the Oncode Drug Repurposing Programme.
I teach 1st year students Biomedical sciences in the subjects of Biomolecules, Metabolism, Enzyme activity and inhibition, and Protein purification. I am also a member of the Educational Advisory Committee of Chemistry at the HLO (university of applied sciences) and member of the Chemical Probes Joint Management Committee within the IMI funded consortium EUbOPEN.
After obtaining my masters in chemistry I did a PhD at the Leiden Institute of Chemistry in the field of chemical biology. I next moved to the Netherlands Cancer Institute to conduct postdoctoral research and spent a short time at the MRC-LMB in Cambridge, UK. Mid-2016 I started at the LUMC in the group of the late professor Huib Ovaa and since 2020 as group leader. The screening facility I am heading has been selected as the center of expertise within the Oncode Drug Repurposing Programme.
I teach 1st year students Biomedical sciences in the subjects of Biomolecules, Metabolism, Enzyme activity and inhibition, and Protein purification. I am also a member of the Educational Advisory Committee of Chemistry at the HLO (university of applied sciences) and member of the Chemical Probes Joint Management Committee within the IMI funded consortium EUbOPEN.
Scientific research
With a background in medicinal chemistry, biochemistry and high-throughput screening my main focus is in the area of Academic Pharma. I am an expert on synthetic tools to study ubiquitin(-like) systems, predominantly their specific proteases, DUBs. I create specialized assay reagents, target-specific inhibitors and activity-based probes, with applications ranging from fundamental structural studies to pharmacologically relevant anti-tumor or antiviral agents (themes: Infection and Cancer). I was the first to develop a small-molecule DUB probe used in vivo, and the first to identify the cross reactivity of 2 DUBs with ISG15. Current work includes the expansion of the HTS center to conduct sophisticated cell-based screens, including phenotypic screens to affect the circadian clock. I also aim to exploit the benefits of our HTS infrastructure for the miniaturized preparation of large compound libraries. I obtained funding from Oncode, Nationaal Groeifonds, IMI, ITN, KWF and NWO-NWA.
